New Drug, Study Method Show Breast Cancer Promise

Novel drug-testing methods show promise for speeding new treatments for breast cancer





A new study shows a drug to prevent breast cancer in high risk patients is not only more effective than current treatments, it also comes with fa... Whether the drug, veliparib, ever makes it to market remains to be seen, but it has shown enough potential to advance to final-phase testing aimed at Food and Drug Administration approval. Bringing a new cancer drug to market usually takes more than a decade and tests in thousands of patients, and costs more than $1 billion. Companies can't afford many studies like that, and patients can't wait years for potentially life-saving new medicines, said Don Berry, a biostatistician at the University of Texas MD Anderson Cancer Center. He helped design the novel analytical method discussed Friday at the San Antonio Breast Cancer Symposium , an international conference. Breast cancer conference: Some treatments can be skipped Researchers testing a drug usually don't see results until they're all in, to prevent biasing the study. But several years ago, an unusual partnership decided to try a new way. For New drug, study method show breast cancer promise original version, visit http://www.cbsnews.com/news/new-drug-study-method-show-breast-cancer-promise/









The I-SPY 2 testing suggests that adding the chemotherapy drug carboplatin and veliparib to usual chemo before surgery improved outcomes for women http://www.kunyit.my/highly-effective-natural-cancer-treatment with "triple negative" breast cancer tumors that are not fueled by estrogen, progesterone or the gene that the medicine Herceptin targets. Up to 20 percent of breast cancers are this type, and they are more common in young women, blacks and Hispanics, and women with certain breast cancer gene mutations. Researchers were able to determine the drug's potential after tests in only 71 women and just six months of treatment. They calculated that tests of only 300 women with triple negative tumors are needed to give a definitive answer, and that the drug has at least a 90 percent probability of success in such patients. If more types of cancer are included, the probability of success drops to 55 percent. The results show that "we can get early reads on something that is worth pursuing" and bail quickly on treatments that don't help, said Dr. For Novel drug-testing methods show promise for speeding new treatments for breast cancer original version, visit http://www.startribune.com/lifestyle/health/235745591.html







Meridian breast cancer treatment options Cancer Care Unveils Technologies that Streamline Breast Cancer Treatment





And, the precision of the treatment means minimal effects on adjacent tissues, steering radiation away from the chest wall and muscles, as well as the heart and lungs, says Douglas A. Miller, M.D., medical director of Radiation Oncology at Jersey Shore. Jersey Shores Faxitron system, also available at Riverview Medical Center, reduces breast biopsy and lumpectomy procedure times, and ultimately improves patient care. Point-of-care specimen radiography allows instant high-resolution digital images of breast biopsy and lumpectomy specimens directly in the operating room. Twenty minutes or more can be saved for the patient under anesthesia, and connectivity allows the surgeon and radiologist to view the image simultaneously. Faxitron allows real time breast specimen imaging in the operating room so that the surgeon can determine if the resection is adequate and if additional margins need to be obtained. This reduces operative time, while allowing the surgeon to remove additional margins at the time of the original surgery in order to avoid follow up surgeries to achieve negative breast margins. For Meridian Cancer Care Unveils Technologies that Streamline Breast Cancer Treatment original version, visit http://newswise.com/articles/meridian-cancer-care-unveils-technologies-that-streamline-breast-cancer-treatment